aTyr Pharma Inc. (ATYR)
NASDAQ: ATYR
· Real-Time Price · USD
3.35
-0.12 (-3.46%)
At close: May 01, 2025, 3:59 PM
3.36
0.15%
After-hours: May 01, 2025, 07:57 PM EDT
-3.46% (1D)
| Bid | 3.34 |
| Market Cap | 298.12M |
| Revenue (ttm) | 235K |
| Net Income (ttm) | -64.02M |
| EPS (ttm) | -0.86 |
| PE Ratio (ttm) | -3.9 |
| Forward PE | -5.8 |
| Analyst | Buy |
| Ask | 3.65 |
| Volume | 993,809 |
| Avg. Volume (20D) | 1,479,634 |
| Open | 3.49 |
| Previous Close | 3.47 |
| Day's Range | 3.34 - 3.49 |
| 52-Week Range | 1.42 - 4.66 |
| Beta | 0.96 |
About ATYR
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connectiv...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 56
Stock Exchange NASDAQ
Ticker Symbol ATYR
Website https://www.atyrpharma.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ATYR stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 376.90% from the latest price.
Stock Forecasts2 months ago
+11.14%
ATyr Pharma shares are trading higher after Leerin...
Unlock content with
Pro Subscription
7 months ago
+7.47%
aTyr Pharma shares are trading higher after Wells Fargo initiated coverage on the stock with an Overweight rating and announced a price target of $17.
